Smooth Drug Development August 2016 News Release

Several new projects are initiated at Smooth Drug Development:

• Smooth Drug Development is awarded with another Patient Support Program. More than 500 patientsa with Multiple Sclerosis will be included into the programm.
• Smooth Drug Development is preparing several literature reviews of clinical and pre-clinical studies.
• Smooth Drug Development is signing an agreement for postmarketing pharmacovigilance activities for several drugs manufactured by different European pharmaceutical companies.
• Smooth Drug Development starts collaboration with a leading Indian pharmaceutical company. Smooth Drug Development will be performing bioequivalence trials for the drug registration in Russia.   
• Our medical writers are writing medical documents for two clinical studies.
• Our clinical team is launching a phase III study in PID/Primary Immunodeficiency. 
• Smooth Drug Development is launching a phase III study with sildenafil.
• Smooth Drug Development is initiating a trial with a pain management medication for an international drug. 

Smooth Drug Development also reached interim targets in several trials:

• Close-out visits were performed in three bioequivalence trials: two bioequivalence trials with a combination drug of Acetylsalicylic acid + Magnesium hydroxide and a bioequivalence trial of a combination drug of Glibenclamide + Metformin.
• An initiation visit was performed in a bioequivalence trial with azithromycin.

What is more, our company assisted a leading institution of The Scientific Research Neurosurgery Institute named after the academician Nikolay Nilovich Burdenk to obtain a clinical trial accreditation for phase I clinical studies. First patients are enrolled at this site into Smooth Drug Development ongoing clinical program. 

Smooth Drug Development opened a new office in Moscow:

The office is located close to a museum of Vladimir Vysotsky, a well known Russian poet, actor and singer.

We also plan to expand our St-Petersburg office soon.